Hyperprogressive disease in patients receiving immune checkpoint inhibitors

Area of Science:

• Oncology
• Immunotherapy
• Cancer Research

Background:

• Hyperprogressive disease (HPD) is an adverse outcome in cancer patients receiving immune checkpoint inhibitors (ICIs).
• HPD is characterized by accelerated disease progression and is linked to a worse prognosis.
• Current understanding lacks a consensus definition and fully elucidated mechanisms for HPD.

Purpose of the Study:

• To review the current understanding of hyperprogressive disease (HPD) in the context of immune checkpoint therapy.
• To highlight the challenges in defining and identifying HPD.
• To discuss potential predictive factors and current management strategies for HPD.

Main Methods:

• Literature review of studies investigating hyperprogressive disease (HPD) in cancer patients treated with immune checkpoint inhibitors.
• Analysis of reported incidence rates, prognostic implications, and potential risk factors for HPD.
• Examination of current diagnostic approaches and management strategies for HPD.

Main Results:

• The incidence of HPD varies widely (4%-29%) across different tumor types.
• HPD is consistently associated with significantly poorer patient prognosis.
• Potential risk factors like MDM2/4 amplification, EGFR mutations, and older age are suggested but lack consistent evidence.

Conclusions:

• Hyperprogressive disease (HPD) presents a significant challenge in immune checkpoint therapy, necessitating further research into its mechanisms.
• Standardized definitions and validated predictive biomarkers are essential for accurate HPD identification and patient management.
• Early imaging and biopsy are currently recommended to mitigate risks associated with HPD and immunotherapy.